Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study

Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients – results of the PALG study ‘PolAZA’

“…Our findings, in contrast to the most studies presented so far, demonstrated that only patient-and [28,29]. The Polish Adult Leukemia Group has documented that lower albumin level significantly increases the risk of serious infections in MDS/AML/CMML patients treated with azacitidine [30]. In our series, albumin level remained independent from ECOG, MDS-CI, HCT-CI and ferritin level.…”

“…Two other independent prognostic markers were: occurrence of serious infection and number of received azacitidine cycles. These results were in accordance with recently published studies and reinforce the view that well-tailored management plays a very important role in obtaining the best outcome [15,27,30]. In the current study, median survival of patients who prematurely discontinued azacitidine treatment was 4 months as compared to 16 months in those who received at least four cycles.…”

Azacitidine-induced hyperglycaemia

“…A systematic review and meta-analysis reported the incidence of neutropaenia and febrile neutropaenia to be 45% and 25%, respectively, in individuals with myeloid neoplasms treated with hypomethylating agents 6. Neutropaenia (<0.8×10 9 /L) significantly increased the infectious risk in a predictive model of myeloid neoplasms treated with azacitidine 7. Neutrophil function may be diminished in myelodysplasia as a result of impairment in multiple steps in granulocyte mobilisation, decreased phagocytosis and impaired microbicidal capacity 8.…”

Current status and achievements of Polish haemato-oncology

“…It was found that red blood cell transfusion dependency [odds ratio (OR) =2.38], neutropenia <0.8 ×10 9 / /L (OR =3.03), platelet count <50 ×10 9 /L (OR =2.63), albumin level <35 g/L (OR =2.04) and ECOG performance status ≥2 (OR =2.19) all had a significant impact on infectious risk. A subset of patients was selected with high risk of infection rate, 73% versus 25%, and worse clinical outcome, 8 versus 29 months survival [20].…”